 ambrisentan |
| Letairis |
Pharmaceutical
company:
Gilead Sciences
www.gilead.com |
Pharmacologic classification: endothelin receptor antagonist
Therapeutic classification: antihypertensive
Pregnancy risk category: X
AVAILABLE FORMS
Tablets: 5, 10 mg
INDICATIONS AND DOSAGES
Pulmonary artery hypertension in patients with class II or III symptoms to improve exercise capacity and delay clinical worsening--
Adults: Initially, 5 mg/day P.O. May be increased to 10 mg/day if tolerated and needed. Tablets shouldn’t be cut, crushed, or chewed.
CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients with known hypersensitivity to any components of the drug, moderate to severe hepatic impairment, pregnancy (a negative pregnancy test is required for women of childbearing age before using this drug).
Use cautiously in breast-feeding women. Not recommended for patients with moderate to severe hepatic impairment.
INTERACTIONS
Drug-drug.
Cyclosporine A: Increased risk of elevated serum levels and toxicity. Avoid use together.
Ketoconazole, omeprazole: Risk of increased levels of ambrisentan when combined. Use together cautiously.
ADVERSE REACTIONS
CNS: headache.
CV: palpitations, peripheral edema.
GI: abdominal pain, constipation, liver injury.
Hematologic: anemia.
Respiratory: nasopharyngitis, sinusitis, dyspnea, nasal congestion.
Other: flushing, birth defects.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
